Elipovimab

Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the targeted elimination of HIV infected cells and is as of 2020 in phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.[1][2]

References

  1. ↑ "GS-9722: FIRST-IN-CLASS EFFECTOR-ENHANCED BROADLY NEUTRALIZING ANTIBODY FOR HIV CURE". CroiConference.Org.
  2. ↑ "Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys". Gilead.com.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.